×
About 46,615 results

ALLMedicine™ Abdominal Pain Center

Research & Reviews  13,628 results

Acute hepatic porphyrias no longer as rare as previously thought
https://www.mdedge.com/internalmedicine/article/260911/gastroenterology/acute-hepatic-porphyrias-no-longer-rare-previously
Carolyn Crist

Jan 30th, 2023 - Although rare, acute hepatic porphyrias (AHPs) may be more common than previously thought, particularly among women between ages 15 and 50, according to a new clinical practice update from the American Gastroenterological Association. For acute at.

Fever and Abdominal Pain in a 13-Year-Old Boy.
https://doi.org/10.1177/00099228221150696
Clinical Pediatrics; Azevedo AC, Miranda S et. al.

Jan 29th, 2023 - Fever and Abdominal Pain in a 13-Year-Old Boy.|2023|Azevedo AC,Miranda S,Silva C,Martins S,Martinho I,|

Food Allergies and Alpha-gal Syndrome for the Gastroenterologist.
https://doi.org/10.1007/s11894-022-00860-7
Current Gastroenterology Reports; Lee CJ, McGill SK

Jan 28th, 2023 - Food allergies are typically not considered as a cause of gastrointestinal (GI) distress without additional allergic symptoms, apart from celiac disease and eosinophilic esophagitis. However, recent reports of patients with alpha-gal syndrome who ...

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
https://clinicaltrials.gov/ct2/show/NCT04026984

Jan 27th, 2023 - Approximately 142 subjects are expected to be enrolled in the study, 1:1 in the Rifamycin SV MultiMatrix (MMX) plus Oral Rescue Therapy (ORT) group and in the placebo tablets plus ORT group respectively. The day of randomization (Visit 1, Day 1), ...

Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
https://clinicaltrials.gov/ct2/show/NCT04027894

Jan 27th, 2023 - Approximately 142 subjects are expected to be enrolled in the study, 1:1 in the Rifamycin SV MultiMatrix (MMX) plus Oral RehydrationTherapy (ORT) group and in the placebo tablets plus ORT group respectively. The day of randomization (Visit 1, Day ...

see more →

Guidelines  21 results

AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: E...
https://doi.org/10.1053/j.gastro.2022.11.034
Gastroenterology Wang B, Bonkovsky HL et. al.

Jan 16th, 2023 - The acute hepatic porphyrias (AHP) are rare, inborn errors of heme-metabolism and include acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and porphyria due to severe deficiency of 5-aminolevulinic acid dehydratase. Ac...

ACR Appropriateness Criteria® Right Lower Quadrant Pain: 2022 Update.
https://doi.org/10.1016/j.jacr.2022.09.011
Journal of the American College of Radiology : JACR; , Kambadakone AR et. al.

Nov 28th, 2022 - This document focuses on imaging in the adult and pregnant populations with right lower quadrant (RLQ) abdominal pain, including patients with fever and leukocytosis. Appendicitis remains the most common surgical pathology responsible for RLQ abdo...

Operative management of acute abdomen after bariatric surgery in the emergency setting:...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516804
World Journal of Emergency Surgery : WJES; De Simone B, Chouillard E et. al.

Sep 28th, 2022 - Patients presenting with acute abdominal pain that occurs after months or years following bariatric surgery may present for assessment and management in the local emergency units. Due to the large variety of surgical bariatric techniques, emergenc...

Blinded Oral Challenges with Lactose and Placebo Accurately Diagnose Lactose Intolerance: A Real-Life Study
https://pubmed.ncbi.nlm.nih.gov/34068318/
Nutrients Rocco A, Compare D et. al.

May 13th, 2021 - Lactose intolerance (LI) is characterized by diarrhea, abdominal pain, or bloating occurring after lactose consumption in patients with lactose malabsorption. The National Institute of Health (NIH) proposed a double-blind placebo testing to identi...

Chronic mesenteric ischemia: Clinical practice guidelines from the Society for Vascular...
https://doi.org/10.1016/j.jvs.2020.10.029
Journal of Vascular Surgery; Huber TS, Björck M et. al.

Nov 11th, 2020 - Chronic mesenteric ischemia (CMI) results from the inability to achieve adequate postprandial intestinal blood flow, usually from atherosclerotic occlusive disease at the origins of the mesenteric vessels. Patients typically present with postprand...

see more →

Drugs  688 results see all →

Clinicaltrials.gov  1,175 results

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
https://clinicaltrials.gov/ct2/show/NCT04026984

Jan 27th, 2023 - Approximately 142 subjects are expected to be enrolled in the study, 1:1 in the Rifamycin SV MultiMatrix (MMX) plus Oral Rescue Therapy (ORT) group and in the placebo tablets plus ORT group respectively. The day of randomization (Visit 1, Day 1), ...

Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
https://clinicaltrials.gov/ct2/show/NCT04027894

Jan 27th, 2023 - Approximately 142 subjects are expected to be enrolled in the study, 1:1 in the Rifamycin SV MultiMatrix (MMX) plus Oral RehydrationTherapy (ORT) group and in the placebo tablets plus ORT group respectively. The day of randomization (Visit 1, Day ...

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

Jan 27th, 2023 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Endosonography-guided Gallbladder Drainage vs Non-endoscopic Treatment in Inoperable Acute Cholecystitis
https://clinicaltrials.gov/ct2/show/NCT05702775

Jan 27th, 2023 - Design Randomized, open-label, low-intervention, superiority clinical trial with parallel groups for the two treatment strategies. Cost study Patients who meet the inclusion criteria and do not meet any exclusion criteria will be invited to partic...

Reducing Pain and Anxiety Through Dietary Fiber Supplementation in Children With Abdominal Pain
https://clinicaltrials.gov/ct2/show/NCT04619095

Jan 26th, 2023 - Background - Mental health and pain problems in early childhood are major risk factors for serious mental health problems into adulthood. These long-term effects point toward the essential need for prevention and early intervention to curbing the ...

see more →

News  2,776 results

Acute hepatic porphyrias no longer as rare as previously thought
https://www.mdedge.com/internalmedicine/article/260911/gastroenterology/acute-hepatic-porphyrias-no-longer-rare-previously
Carolyn Crist

Jan 30th, 2023 - Although rare, acute hepatic porphyrias (AHPs) may be more common than previously thought, particularly among women between ages 15 and 50, according to a new clinical practice update from the American Gastroenterological Association. For acute at.

FDA Greenlights First Drug for ESR1-Mutated Breast Cancer
https://www.medpagetoday.com/hematologyoncology/breastcancer/102880

Jan 30th, 2023 - The FDA approved the selective estrogen receptor (ER) degrader elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression...

Proof lacking for dual-targeted therapy benefit in IBD
https://www.mdedge.com/internalmedicine/article/260796/gastroenterology/proof-lacking-dual-targeted-therapy-benefit-ibd
Neil Osterweil

Jan 25th, 2023 - AURORA, COLO. – Only sparse evidence supports the use of dual-targeted therapy for patients with severe, refractory inflammatory bowel disease (IBD) -- and additional evidence will be hard to come by, according to a leading IBD researcher.

FDA OKs First Targeted Treatment for HER2-Positive Colorectal Cancer
https://www.medpagetoday.com/hematologyoncology/coloncancer/102708

Jan 19th, 2023 - The FDA has granted accelerated approval to tucatinib (Tukysa) in combination with trastuzumab (Herceptin) for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer who have progressed following treatment wi...

Be Alert For Ectopic Pregnancy After Self-Managed Abortion
https://www.medpagetoday.com/obgyn/abortion/102689

Jan 18th, 2023 - Clinicians in the emergency department (ED) and primary care settings should be prepared to spot complications of self-managed abortion, according to a case report. A patient who had attempted self-managed abortion presented to the ED with a ruptu...

see more →

Patient Education  358 results see all →